Erdafitinib
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
lanthanum carbonate
Phosphate binder · Phosphate-binding agent
Phosphate binderPhosphate-binding agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- ErdafitinibSevereDatabaseDDInter
Mechanism
A poorly permeable trivalent cation that is highly effective in treating hyperphosphatemia.
Indications
hyperphosphatemia associated with chronic kidney disease–mineral bone disease (CKD-MBD)treatment and prevention of CKD-MBD
Contraindications
- bowel obstruction
Side effects
Common
gastrointestinal side effects
Serious
- gastrointestinal obstruction
- ileus
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Chronic kidney disease — mineral and bone disorder
KDIGO · Nephrology · 2017
Chronic kidney disease — assessment and management
NICE · Nephrology · 2021
Cardiovascular disease prevention
ESC · Cardiology · 2021
Primary prevention of cardiovascular disease
AHA · Cardiology · 2019
Other Phosphate binder drugs
Ask House about lanthanum carbonate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team